| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1097/00001665-200309000-00009 |
| P953 | full work available at URL | http://journals.lww.com/00001665-200309000-00009 |
| P698 | PubMed publication ID | 14501323 |
| P2093 | author name string | Brian Berman | |
| Varee N. Poochareon | |||
| P2860 | cites work | Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug | Q29396548 |
| Treatment of keloid scars with pulsed dye laser and intralesional steroid | Q30699421 | ||
| In-situ irradiation of keloid scars with Nd:YAG laser | Q30728032 | ||
| Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments | Q30847368 | ||
| On the nature of hypertrophic scars and keloids: a review | Q33747990 | ||
| Keloidal scars: a review with a critical look at therapeutic options | Q34504304 | ||
| International clinical recommendations on scar management. | Q34763000 | ||
| Failure of carbon dioxide laser excision of keloids | Q35208904 | ||
| Argon and carbon dioxide laser treatment of hypertrophic and keloid scars | Q36604917 | ||
| Treatment of keloid sternotomy scars with 585 nm flashlamp-pumped pulsed-dye laser | Q36702717 | ||
| Improvement of erythematous and hypertrophic scars by the 585-nm flashlamp-pumped pulsed dye laser. | Q36751099 | ||
| In Search of the Optimal Treatment of Keloids: Report of a Series and a Review of the Literature | Q37114185 | ||
| Retinoic acid in the treatment of keloids | Q39236590 | ||
| Evaluation of various methods of treating keloids and hypertrophic scars: a 10-year follow-up study | Q39500821 | ||
| Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts | Q40804244 | ||
| Pharmacologic Control of Surface Scarring in Human Beings | Q41634613 | ||
| Prevention and treatment of keloids with intralesional verapamil | Q42162473 | ||
| The effects of a single dose of 5-fluorouracil on keloid scars: a clinical trial of timed wound irrigation after extralesional excision | Q43769093 | ||
| Are keloids really "gli-loids"?: High-level expression of gli-1 oncogene in keloids | Q43770695 | ||
| Infantile hemangioma: clinical resolution with 5% imiquimod cream | Q44033000 | ||
| Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids | Q44149660 | ||
| Intralesional interferon gamma treatment for keloids and hypertrophic scars | Q44962113 | ||
| Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro | Q46058637 | ||
| Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectin | Q46594346 | ||
| Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages | Q53788107 | ||
| A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloidal scarring. Clinical and histologic findings | Q68361525 | ||
| Calcium antagonists retard extracellular matrix production in connective tissue equivalent | Q68613582 | ||
| Topical putrescine (Fibrostat) in treatment of hypertrophic scars: phase II study | Q70814442 | ||
| Failure of interferon-alpha 2b in the treatment of mature keloids | Q71538556 | ||
| Keloids | Q71847664 | ||
| Intralesional interferon alpha-2b has no effect in the treatment of keloids | Q72520455 | ||
| Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections | Q73874835 | ||
| Treatment of the keloid: what is new? | Q77461310 | ||
| Carbon dioxide laser ablation associated with interferon alfa-2b injections reduces the recurrence of keloids | Q77647358 | ||
| Topical tamoxifen--a potential therapeutic regime in treating excessive dermal scarring? | Q77667797 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | surgery | Q40821 |
| P304 | page(s) | 654-657 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | Journal of Craniofacial Surgery | Q15759095 |
| P1476 | title | New therapies for the management of keloids | |
| New Therapies for the Management of Keloids | |||
| P478 | volume | 14 |
| Q50220929 | A Selenium-Enriched Ziyang Green Tea Polysaccharide Induces Bax-Dependent Mitochondrial Apoptosis and Inhibits TGF-β1-Stimulated Collagen Expression in Human Keloid Fibroblasts via NG2 Inactivation |
| Q54365116 | Collagen triple helix repeat containing-1 inhibits transforming growth factor-b1-induced collagen type I expression in keloid. |
| Q33675721 | Combination therapy with butyrate and docosahexaenoic acid for keloid fibrogenesis: an in vitro study |
| Q51497321 | Conditioned medium from keloid keratinocyte/keloid fibroblast coculture induces contraction of fibroblast-populated collagen lattices. |
| Q34911441 | Heat shock proteins modulate keloid formation |
| Q36240167 | Hsp70 Knockdown by siRNA Decreased Collagen Production in Keloid Fibroblasts. |
| Q24595036 | Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies |
| Q36012541 | Inhibition of collagen fibril formation |
| Q39977027 | Keloid formation after syndactyly release in patients with associated macrodactyly: management with methotrexate therapy |
| Q33910210 | Keloids: Pathogenesis, Clinical Features, and Management |
| Q36784280 | Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid--two case reports and literature review. |
| Q33918530 | Management of ear lobule keloids using 980-nm diode laser |
| Q34699606 | Management of keloids and hypertrophic scars: current and emerging options |
| Q44894377 | Nanosilver as a novel agent in keloid therapy. |
| Q37222825 | Prevention and reduction of scarring in the skin by Transforming Growth Factor beta 3 (TGFbeta3): from laboratory discovery to clinical pharmaceutical |
| Q52576451 | Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-beta1-induced collagen synthesis. |
| Q30772411 | Resolution of retracted scar after 585-nm pulse dye laser surgery |
| Q35010481 | Strategic management of keloid disease in ethnic skin: a structured approach supported by the emerging literature. |
| Q40232314 | The role of the activin system in keloid pathogenesis. |
Search more.